Ten million new cases of HIV projected amid global reduction in funding
New HIV infections have declined by 39% since 2010, from 2.1 million to 1.3 million in 2023, according to UNAIDS. …
Post
-
-
AD/PD 2025: Further evidence for efficacy of TauRx’s LMTX, despite lack of true placebo comparator
On 5 April 2025 at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, held in Vienna, Austria, during …
-
AD/PD 2025: Long-term data shows Anavex’s Blarcamesine benefits in early Alzheimer’s
On 5 April 2025, at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases held in Vienna, Austria, during …
-
Rhythm seeks market expansion for Imcivree following Phase III victory
Rhythm Pharmaceuticals is pursuing approval for its rare obesity disorder drug Imcivree in acquired hypothalamic obesity after it showed a …
-
Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial
US-based biotechnology company Sonnet BioTherapeutics has reported positive safety outcomes from a Phase Ib/IIa trial of high-dose SON-1010 (IL12-FHAB) in …
-
Sarepta and Roche aim to resume paused Elevidys trials following patient death
Sarepta Therapeutics and Roche are looking to get approval to continue clinical trials of their Duchenne muscular dystrophy gene therapy …
-
J&J’s psoriatic arthritis therapy trial meets endpoints
US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody …
-
CIRM awards $8m to Tr1X for trial of GvHD prevention drug candidate TRX103
The California Institute for Regenerative Medicine (CIRM) in California, US, has awarded an $8m grant to biotechnology company Tr1X to …
-
AD/PD 2025: Spotlight on ARIA as new data and evidence emerges for Alzheimer’s DMT use
Following the launch of the first disease-modifying therapies (DMTs) for Alzheimer’s disease (AD), a key theme at the AD/PD 2025 …
-
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s
A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop in the multifunctional …
-
UK’s ARIA funds Lindus Health to develop safe AI for trial design
The UK’s research and development (R&D) funding agency ARIA has granted funds to anti-clinical research organisation (CRO) Lindus Health for …
-
Are DCTs truly more sustainable?
During the pandemic, sponsors and biotechs started running decentralised clinical trials (DCTs) to keep research going when patients had less …
-
Lundbeck’s superagonist prompts 61.2% seizure reduction
Lundbeck’s receptor superagonist designed to treat seizures associated with developmental and epileptic encephalopathies (DEEs) has seen a 61.2% reduction in total …
-
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN
Intellia Therapeutics has commenced subject dosing in the randomised pivotal Phase III MAGNITUDE-2 trial of nexiguran ziclumeran (nex-z) for hereditary …
-
AD/PD 2025: Roche’s Brainshuttle technology promises next generation of amyloid beta mAbs
At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium …
